Evidence map›Paper›PMID 41788794›Full record

ArticleFrontiers in pharmacology2026

Xiwen Sun, Li Liu, Wenbo Jiao, Ting Ren, Ran Zhao, Zirui Tan, Ziye Jiang, Jing Wang, Bo Li, Xiaoyu Zhang and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiwen SunJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
Li LiuThe Affiliated Hospital Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Wenbo JiaoThe Affiliated Hospital Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Ting RenSchool of Pharmaceutical Sciences, Jilin Medical University, Jilin, China.
Ran ZhaoJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
Zirui TanSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China.
Ziye JiangJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
Jing WangThe Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Bo LiSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China.
Xiaoyu ZhangJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
Lili JiaoJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Based on prior evidence that red ginseng pectin GPS-1 ameliorates T2DM in rats and modulates gut microbiota, we report for the first time that GPS-1 interacts with the gut microbiota of T2DM rats, as demonstrated through an Materials and methods: GPS-1 was subjected to simulated salivary-gastrointestinal digestion Results: GPS-1 was highly resistant to Conclusion: This study demonstrates that the hepatoprotective effect of GPS-1 depends on gut microbial fermentation. GPS-1 resists digestion but is degraded by the microbiota, enriching

Indexed as

ginsengHepG2 cellsin vitro digestion and fermentationoxidative stresspolysaccharide

Identifiers

PMID41788794
PMCPMC12957194

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.